JAMESTOWN
20.12.2019 12:32:04 CET | Business Wire | Press release
U.S. real estate investment and management company Jamestown , most notably known for projects like Chelsea Market in New York, today announced it has acquired Rotterdam’s historic Groot Handelsgebouw, its first large format acquisition in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191220005035/en/
The 122,000-square meter (approximately 1.3 million square foot) historic structure, located in the heart of Rotterdam next to the Central Station and 20 minutes from Schiphol airport, is emblematic of the city’s redevelopment after World War II. The building will now become a symbol of the innovation economy. Built in 1953 to help fulfil an acute need for office space Groot Handelsgebouw has become one of the largest mixed-use buildings in the Netherlands housing more than 450 businesses. Jamestown acquired the building from an investment vehicle managed by real estate private equity firm HighBrook Investors for a purchase price of €289 million. HighBrook had previously acquired the asset in July 2018 for approximately €169 million through an off-market public-to-private transaction involving the legacy Dutch listed company (EuroNext: GROHA).
“Groot Handelsgebouw is at the heart of Rotterdam’s history of growth and regeneration; we hope to continue that legacy with a new chapter through creating a hub for the new innovation economy,” said Michael Phillips, President of Jamestown.
Jamestown is a design-focused real estate company whose mission is to transform iconic spaces into innovation hubs and community centers. Its retail, local community, and mixed-use projects include Chelsea Market and Industry City in New York, Ghirardelli Square in San Francisco, Ponce City Market in Atlanta, and The Innovation and Design Building in Boston. Groot Handelsgebouw fits this diverse portfolio of adaptive reuse projects and is the first transaction led by the company’s new European team. Their Netherland’s asset management group is based in Amsterdam out of the historic bicycle factory A Factorij, which Jamestown entered into a partnership on in 2018.
HighBrook was advised on the transaction by Jones Day and Loyens & Loeff as well as its Asset Manager, Equity Estate. Jamestown was advised by Greenberg Traurig.
About Jamestown
Jamestown, LP was established in 1983 as an investment and management company focused on income-producing real estate in the United States. Jamestown companies employ approximately 450 people worldwide with headquarters in Atlanta, Georgia, and Cologne, Germany. The company has offices in Amsterdam, Bogotá, Boston, Los Angeles, New York, and San Francisco.
Since its founding, Jamestown has executed transactions in excess of $35 billion. As of 30 September 2019, the company has assets under management of $11.5 billion. Capital sources with a long term investment horizon are institutional investors, retail investors, and separate accounts.
As well as the traditional functions of a real estate management company, Jamestown possesses internal expertise that adds value to all aspects of the real estate business. Its in-house capabilities in Development & Construction, Architecture & Design, Sustainability, Retail Leasing, Creative & Marketing, and Food & Beverage curation, Jamestown maximizes value throughout an asset’s ownership period. See also www.jamestownlp.com .
About HighBrook Investors
HighBrook Investors is a private equity real estate manager that specializes in sourcing and identifying unique opportunities for value investing across market cycles. We utilize our collective experience investing in private, public, domestic, and developed international markets to identify situational opportunities across property types at optimal stages of the investment cycle. The firm was founded in 2010 and operates through its main offices in New York and London.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191220005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom